U.S. Markets closed

Khiron Life Sciences Corp. (KHRNF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.3621-0.0079 (-2.14%)
At close: 3:48PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3700
Open0.3498
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.3469 - 0.3700
52 Week Range0.2161 - 1.6000
Volume197,649
Avg. Volume135,574
Market Cap41.542M
Beta (5Y Monthly)1.95
PE Ratio (TTM)N/A
EPS (TTM)-0.3020
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Khiron Launches Solar Panel Plant In Colombian Cannabis Facility
    Benzinga

    Khiron Launches Solar Panel Plant In Colombian Cannabis Facility

    Khiron Life Sciences (OTC: KHRNF) has installed the first solar panel plant in Tolima, Colombia for a cannabis production complex. The company teamed up with ReFeel, a renewable energy company, on the initiative. The park counts 2,600 solar panels, delivering an annual production of 700 kilowatt-hours.CO2 emission is expected to reduce by about 570 tons per year."This solar park will allow us to save energy costs and self-generate 40% of our energy need while reducing CO2 emissions by 570 tons per year," said Khiron Life Sciences CEO and Co-Founder Alvaro Torres. "This project is closely aligned with our higher purpose of positively impacting people's quality of life."Flavia Santoro, President of Procolombia, explained that the project not only allows diversifying energy generation, but it also reduces dependence on water."Additionally, it opens the new frontier to promote national development," he said. "We are committed to this from the Government and ProColombia to promote the arrival of new investments in the sector. "The Italian company ReFeel will be in charge of the maintenance and operation of the infrastructure.RELATED: UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia ClinicPhoto from press releaseSee more from Benzinga * UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic * Cannabis Stock Gainers And Losers From July 27, 2020 * Cannabis Stock Gainers And Losers From July 24, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic
    Benzinga

    UK's Sapphire Medical Funds First Cannabis Treatment, While Khiron Backs Colombia Clinic

    Medical marijuana is gaining more traction in international health care systems.In one scenario, Sapphire Medical Foundation announced the first UK patient to be granted full cannabis medicine treatment funding. Also, Khirion Life Sciences announced the opening of the first medical marijuana clinic in Colombia.UK Funding Sapphire Medical Foundation will fund a patient's fibromyalgia and rheumatoid arthritis treatment for at least one year.The organization's aim is to decrease the economic barriers to access cannabis-based treatments. According to Health Europa, most medical marijuana patients in the UK receive their prescriptions from the private sector, with almost no reimbursement. This makes it unaffordable for a large number of potential-patients.The patient is a 38-year old teacher named Kirran. Her last name has not been disclosed."My pain stops me doing the career I love. I love teaching and being in the classroom, for me there is nothing more rewarding and satisfying," she said. "The foundation grant is a beacon of hope for me in amidst the darkness. It represents the hope that I won't always have to live my life like this, that one day I may be able to return to teaching, regain a social life, and be able to live my life instead of feeling my life is passing me by."England Rugby player George Kruis and Trustee of the Foundation praised the development."Sapphire Medical Foundation gives hope to patients who may benefit from cannabis-based medicines but are unable to afford the current cost of treatment," he said. "With further fundraising, we will help many more patients and I am glad to be a part of it."Colombia's Clinic Colombia's first medical marijuana clinic has been inaugurated. The objective is to treat neurological pathologies as Parkinson's disease, epilepsy, insomnia, chronic headaches, anxiety and depression.Khiron Life Sciences has invested approximately CA$10 million into this clinic based on northern Bogota.The 22,600 square-foot facility is expected to treat 65,000 patients per year.Patients from all regions of Colombia will be able to access the treatments offered by the medical center with the use of its virtual telemedicine platform."We have invested to offer a face-to-face and virtual healthcare model that combines traditional medicine with different complementary alternatives, oriented to the diagnosis, treatment and timely recovery of each patient, applying principles of integrative medicine, offering multidisciplinary care and therapeutic alternatives with medical cannabis for patients who require it, in order to improve their quality of life," Rayet Harb, head of the clinic stated on the press release photo via unsplashSee more from Benzinga * Cannabis Stock Gainers And Losers From July 27, 2020 * Cannabis Stock Gainers And Losers From July 24, 2020 * New York Senate Widens Marijuana Offense Release Terms(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Khiron Provides Corporate Update: Surpasses 1,000 Medical Cannabis Patient Prescription Milestone
    PR Newswire

    Khiron Provides Corporate Update: Surpasses 1,000 Medical Cannabis Patient Prescription Milestone

    Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF), (Frankfurt: A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe, is pleased to provide a corporate update on its commercial operations ahead of Q2 earnings which will be announced on August 24th 2020. The update reflects the Company's revenue generation activities and continued position as the only company with medical cannabis sales in Colombia.